Previously, OPN was described as a protective factor against postmenopausal osteoporosis development, while OPG is a well‐known inhibitor of osteoclastogenesis that protects against age‐dependent osteoporosis development. Here, TNFRSF11B is linked to postmenopausal osteoporosis.